Canine Petechiae and Ecchymoses: Hemostasis Workup

Bottom line

Canine petechiae and ecchymoses prioritize a primary hemostatic defect but do not diagnose thrombocytopenia or immune thrombocytopenia. Stabilize clinically important hemorrhage, define whether the phenotype is primary, secondary, or mixed, confirm platelet number on a smear, and interpret coagulation screening in context. Then pursue mechanism-directed testing for consumption, immune destruction, impaired production, platelet dysfunction, factor deficiency, fibrinolysis, or vascular disease.

Triage and phenotype

Assess mentation, perfusion, mucous membranes, capillary refill, pulse quality, respiratory effort, blood pressure, and point-of-care PCV or hematocrit with total solids. Map cutaneous, oral, conjunctival, retinal, nasal, gastrointestinal, urinary, procedural, and cavitary bleeding. Minimize traumatic sampling and nonessential invasive procedures until the hemostatic defect is characterized.

Petechiae, ecchymoses, mucosal hemorrhage, and immediate persistent oozing favor primary hemostasis. Delayed or recurrent deep-tissue hemorrhage, hematoma, hemarthrosis, and cavitary bleeding favor a coagulation-factor defect. Merck emphasizes this distinction while noting that DIC and other systemic syndromes can disrupt several components concurrently.[2] Local trauma, ulceration, or a mass still needs to be separated from generalized bleeding.

Directed history and examination

Establish onset, progression, prior episodes, and spontaneous versus procedure-associated bleeding. Record surgery, venipuncture, dental work, trauma, pregnancy, transfusion, and family history. Review breed-associated macrothrombocytopenia, von Willebrand disease, and factor deficiencies without allowing breed to override the current phenotype.

Build a complete drug and supplement timeline, including aspirin or NSAIDs, antimicrobials, estrogens, chemotherapy, anticoagulants, and recently discontinued products. Ask specifically about anticoagulant rodenticide access. Document tick exposure, residence and travel, imported-dog history, systemic illness, fever, weight loss, and neoplasia signs. Examine all skin and accessible mucosa, fundi when feasible, joints, spleen, lymph nodes, and body cavities. Cornell recommends a platelet count, hemogram, chemistry profile, and coagulation screening when unexplained bleeding is present.[4]

Confirm platelet number before classifying thrombocytopenia

Obtain a CBC with manual smear review. Inspect the smear body and feathered edge for clumps, estimate platelet number in the monolayer, and assess platelet size and morphology. Resample when clumping prevents interpretation. The ACVIM ITP algorithm begins with a platelet count below 100,000/µL confirmed by slide assessment; persistent thrombocytopenia should be followed with consistent methodology.[1]

Interpret anemia and regeneration alongside platelet findings, and identify leukopenia, neutropenia, atypical cells, or pancytopenia. Consider artifact, consumption from major hemorrhage or pathologic thrombosis, immune or drug-associated destruction, infectious disease, reduced marrow production, splenic sequestration, and inherited macrothrombocytopenia. Merck notes that acquired thrombocytopenia commonly reflects a broader systemic process and that analyzer counts may be artifactually low.[3]

Screen secondary hemostasis and DIC deliberately

Pair PT with aPTT; add fibrinogen and, when DIC is plausible, D-dimer or FDP and antithrombin. Chemistry and urinalysis assess hepatic, renal, inflammatory, and occult-bleeding contributors. Interpret results against sample quality and the laboratory reference interval. Underfilled citrate tubes, difficult venipuncture, delayed processing, and instrumentation not optimized for rapidly clotting canine plasma can mislead.

Normal PT and aPTT do not exclude platelet disease, von Willebrand disease, vascular disease, fibrinolytic defects, or mild factor deficiencies. Prolongation does not prove that the measured abnormality caused the bleeding. Cornell recommends using PT and aPTT as pathway screens and selecting factor assays or other specialized tests from the combined pattern.[4]

When anticoagulant exposure is plausible, integrate the product and timing with serial coagulation results rather than waiting for visible hemorrhage. The anticoagulant rodenticide reference covers toxin-specific interpretation.

Mechanism-directed next tests

For adequate platelet numbers with a mucocutaneous phenotype, consider von Willebrand factor antigen or activity and validated platelet-function testing. Use buccal mucosal bleeding time selectively and avoid creating an unnecessary wound in a patient with active hemorrhage or severe thrombocytopenia. For a secondary-hemostatic pattern, use PT/aPTT relationships, fibrinogen, exposure history, hepatic assessment, and selective factor testing.

For confirmed thrombocytopenia, test infectious disease according to geography and exposure rather than sending an indiscriminate panel. The ACVIM review found high-level evidence that Ehrlichia canis can trigger ITP, while multiple mechanisms may contribute to thrombocytopenia.[1] The tick-borne disease antimicrobial reference provides organism-specific context after testing is selected. Use thoracic and abdominal imaging when neoplasia, systemic inflammation, splenic disease, or occult hemorrhage is plausible.

Suspected ITP: avoid shortcut diagnoses

Primary ITP remains a diagnosis of exclusion. Platelet- or megakaryocyte-associated antibodies may support an immune component but are not diagnostic, and ACVIM does not recommend routine measurement. Routine MPV, plateletcrit, and immature platelet fraction are also not recommended to diagnose primary ITP; reticulated platelets may provide weak supportive evidence where available.[1]

Bone marrow examination is not a routine diagnostic or prognostic test for primary ITP. Consider it for otherwise unexplained additional cytopenias, suspected production failure, or atypical findings that would change management. Do not use admission platelet count alone to predict outcome or set treatment intensity; integrate bleeding score or burden, anemia, melena, perfusion, concurrent disease, and serial response.[1] The canine melena workup is relevant when gastrointestinal blood loss is present.

The consumer bruising and petechiae guide supports owner observation and escalation without assigning a diagnosis from appearance.

Frequently Asked Questions

Do petechiae prove thrombocytopenia?

No. They prioritize primary hemostatic disease, but platelet dysfunction, von Willebrand disease, vasculopathy, and mixed disorders can produce a similar phenotype. Confirm platelet number and integrate the complete hemostatic profile.

How should an unexpectedly low automated platelet count be confirmed?

Review the smear body and feathered edge for clumps, estimate platelet number in the monolayer, assess platelet size and morphology, and resample when clumping or collection artifact prevents interpretation.

Do normal PT and aPTT exclude a bleeding disorder?

No. They do not exclude thrombocytopenia, platelet dysfunction, von Willebrand disease, vascular disease, fibrinolytic defects, or mild factor deficiencies below assay sensitivity.

Is a platelet antibody test diagnostic for primary ITP?

No. A positive platelet- or megakaryocyte-associated antibody result can support an immune contribution, but ACVIM does not recommend routine testing and the result does not establish primary ITP.

When is bone marrow evaluation indicated in a thrombocytopenic dog?

It is not routine for primary ITP. Consider it when additional cytopenias remain unexplained, production failure or marrow disease is plausible, or atypical findings would make the result management-relevant.

Should admission platelet count determine prognosis in canine ITP?

No. Platelet count may relate to presenting hemorrhage but should not be used alone to predict outcome or guide treatment intensity. Integrate bleeding burden, anemia, perfusion, concurrent disease, and trajectory.